Table 2.

Baseline patient and disease characteristics by baseline EGFR-activating mutation subgroup and by treatment arms.

TotalEx19delEx21L858R
Ex19del (N = 243)Ex21L858R (N = 204)RAM+ERL (N = 123)PBO+ERL (N = 120)RAM+ERL (N = 99)PBO+ERL (N = 105)
Sex, n (%)Female146 (60)136 (67)74 (60)72 (60)66 (67)70 (67)
Age in years, median (range)63 (23–84)66 (41–89)64 (27–84)63 (23–83)67 (44–86)66 (41–89)
RaceaAsian174 (72)170 (83)89 (72)85 (71)81 (82)89 (85)
Caucasian67 (28)33 (16)34 (28)33 (28)18 (18)15 (14)
Smoking history, n (%)Never144 (59)127 (62)71 (58)73 (61)61 (62)66 (63)
ECOG performance status, n (%)0131 (54)103 (51)65 (53)66 (55)50 (51)53 (51)
Disease classification, n (%)Primary metastatic207 (85)178 (87)103 (84)104 (87)91 (92)87 (83)
Recurrent metastatic36 (15)26 (13)20 (16)16 (13)8 (8)18 (17)
Metastases sites, n (%)Lung224 (92)188 (92)112 (91)112 (93)93 (94)95 (91)
Lymph152 (63)127 (62)78 (63)74 (62)64 (65)63 (60)
Bone63 (26)69 (34)35 (29)28 (23)33 (33)36 (34)
Liver26 (11)19 (9)11 (9)15 (13)10 (10)9 (9)
Other146 (60)104 (51)70 (57)76 (63)48 (49)56 (53)
Number of metastatic sites129 (12)23 (11)12 (10)17 (14)9 (9)14 (13)
290 (37)86 (42)50 (41)40 (33)46 (47)40 (38)
399 (41)74 (36)50 (41)49 (41)32 (32)42 (40)
420 (8)15 (7)11 (9)9 (8)9 (9)6 (6)
≥55 (2)6 (3)05 (4)3 (3)3 (3)
  • Abbreviations: ECOG, Eastern Cooperative Oncology Group; n, number of patients per category; N, number of patients in population.

  • aPBO + ERL arm included three Other: one Black or African American, one Missing (ex19del group), one American Indian or Alaska Native (ex21L858R group).